New drug could help dermatomyositis patients ditch steroids
NCT ID NCT04972760
First seen Jun 08, 2026 · Last updated Jun 13, 2026 · Updated 2 times
Summary
This study tests whether baricitinib, a JAK inhibitor, can help people with dermatomyositis achieve significant improvement without needing steroids. About 62 adults with active disease will receive either baricitinib or a placebo alongside standard care. The goal is to see if baricitinib allows patients to taper off steroids while still controlling their condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pitie-Salpêtrière hospital APHP
RECRUITINGParis, 75013, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.